The ArteraAI Prostate Test is transforming the risk stratification landscape for treating localized prostate cancer. Watch this webinar to learn about how its clinical utility could benefit you, your patients and practice.
The ArteraAI Prostate Test was recently included as the first and only prognostic and predictive AI test in the NCCN Guidelines® for localized prostate cancer. Unlike genomic tests, the ArteraAI Prostate Test is a digital pathology test with a turnaround time of 2-3 days upon receipt of the biopsy slide.
Dr. Adam Cole from PathNet joins Dr. Timothy Showalter, Artera Chief Medical Officer, to discuss how the test works, its scientific validation through multiple randomized trials, and reviews a few real-life case results and its impact on patient treatment choices.
Fill out the form to view the recording…
